[Preliminary study of immunity and safety of recombinant adenovirus expressing rotavirus structural proteins in rhesus monkeys].
OBJECTIVE
To preliminarily evaluate the immunity and safety of the recombinant adenoviruses expressing rotavirus structural proteins VP7 and VP6 in rhesus monkeys to lay a foundation for the development of novel genetic engineering vaccine against rotavirus.


METHODS
Baby monkeys were immunized with the recombinant adenoviruses intranasally or orally. Serum IgG against rotavirus was measured with ELISA. During the course of the immunization, besides the daily monitoring of body temperature, weight and clinical symptoms, the routine blood and urine tests and liver and kidney function tests were also conducted.


RESULTS
Monkeys immunized via intranasal or oral routes could both generate serum IgG against rotavirus. During the immunization, the temperature of monkeys was normal and body weight raise stably. Both routine blood and urine tests and liver and kidney function tests showed no significant alteration compared with the control group.


CONCLUSIONS
The immunization with the recombinant adenoviruses expressing rotavirus antigens is able to induce rotavirus specific efficient immune responses and is safe to baby rhesus monkeys. The preliminary results implied that the recombinant adenoviruses could be an ideal vaccine for rotavirus and lay a foundation for further studies.
Li
Yong
Y
Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China.
Jiang
Qin-fang
QF
Wang
Jian-wei
JW
Chen
Yu
Y
Wang
Min
M
Li
Chun-hua
CH
Zhang
Cai-hong
CH
Dai
Cheng-bo
CB
Yu
Xiu-ping
XP
Dai
Jie-jie
JJ
Li
Qi-han
QH
Hong
Tao
T
D000256:Adenoviridae / Q000235:genetics* / Q000378:metabolism; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D000956:Antigens, Viral / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D036022:Capsid Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D005818:Genetic Engineering; D008253:Macaca mulatta; D012401:Rotavirus / Q000235:genetics* / Q000276:immunology; D012400:Rotavirus Infections / Q000276:immunology / Q000517:prevention & control; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology; D015678:Viral Structural Proteins / Q000235:genetics
D000914:Antibodies, Viral; D000956:Antigens, Viral; D036022:Capsid Proteins; C061332:VP6 protein, Rotavirus; C050779:VP7 protein, Rotavirus; D014614:Vaccines, Synthetic; D015678:Viral Structural Proteins